{"id":"W4224035333","doi":"10.1038/s41591-022-01754-x","title":"Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":170,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Daiichi Sankyo Europe; Foundation Medicine; EMD Serono; Genentech; Lunit; Mirati Therapeutics; Novocure; Jazz Pharmaceuticals; F. Hoffmann-La Roche; Roche; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Oncology; Lung cancer; Atezolizumab; Internal medicine; Biomarker; Cancer; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003567523,0.000156904,0.0001861776,0.00007580483,0.0001544985,0.00001009615,0.0002678489,0.0001104596,0.0001979651],"category_scores_gemma":[0.0002472786,0.0001192517,0.00008761726,0.0001760938,0.00007001669,0.000001136796,0.00007873827,0.0003039757,4.928146e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006809312,"about_ca_system_score_gemma":0.0005311226,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004103233,"about_ca_topic_score_gemma":0.0002292181,"domain_scores_codex":[0.9989279,0.00004706085,0.0002477372,0.0003295002,0.0002139327,0.0002338865],"domain_scores_gemma":[0.9993245,0.0001544678,0.0001254366,0.000242687,0.00008708066,0.00006585314],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.09561056,0.001874071,0.001323897,0.0003929648,0.0004838668,0.0003469396,0.001232844,0.007870412,0.6722612,0.0004376394,0.2081348,0.0100308],"study_design_scores_gemma":[0.3439479,0.00702041,0.0007387307,0.00009375731,0.0006309465,0.00006810533,0.0007190133,0.01959883,0.08177792,0.0002966384,0.5443965,0.000711279],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816197,0.009898691,0.0001978999,0.004953702,0.001140605,0.001322301,0.000383667,0.000005805317,0.0004776691],"genre_scores_gemma":[0.9924445,0.000103046,0.000101963,0.003731554,0.001590039,0.0008623757,0.0008397843,0.00002766117,0.0002990551],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5904833,"threshold_uncertainty_score":0.4862942,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007360873761604151,"score_gpt":0.2999871591720812,"score_spread":0.292626285410477,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}